Literature DB >> 27281570

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.

Carole J Henry Dunand1, Paul E Leon2, Min Huang1, Angela Choi2, Veronika Chromikova3, Irvin Y Ho1, Gene S Tan3, John Cruz4, Ariana Hirsh3, Nai-Ying Zheng1, Caitlin E Mullarkey3, Francis A Ennis5, Masanori Terajima5, John J Treanor6, David J Topham7, Kanta Subbarao8, Peter Palese9, Florian Krammer10, Patrick C Wilson11.   

Abstract

Pathogenic H7N9 avian influenza viruses continue to represent a public health concern, and several candidate vaccines are currently being developed. It is vital to assess if protective antibodies are induced following vaccination and to characterize the diversity of epitopes targeted. Here we characterized the binding and functional properties of twelve H7-reactive human antibodies induced by a candidate A/Anhui/1/2013 (H7N9) vaccine. Both neutralizing and non-neutralizing antibodies protected mice in vivo during passive transfer challenge experiments. Mapping the H7 hemagglutinin antigenic sites by generating escape mutant variants against the neutralizing antibodies identified unique epitopes on the head and stalk domains. Further, the broadly cross-reactive non-neutralizing antibodies generated in this study were protective through Fc-mediated effector cell recruitment. These findings reveal important properties of vaccine-induced antibodies and provide a better understanding of the human monoclonal antibody response to influenza in the context of vaccines.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27281570      PMCID: PMC4901526          DOI: 10.1016/j.chom.2016.05.014

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  52 in total

1.  Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

Authors:  David J DiLillo; Peter Palese; Patrick C Wilson; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

Review 3.  Immunity to influenza in man.

Authors:  R B Couch; J A Kasel
Journal:  Annu Rev Microbiol       Date:  1983       Impact factor: 15.500

4.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

5.  Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.

Authors:  Zhongying Chen; Mariana Baz; Janine Lu; Myeisha Paskel; Celia Santos; Kanta Subbarao; Hong Jin; Yumiko Matsuoka
Journal:  J Virol       Date:  2014-04-09       Impact factor: 5.103

6.  A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.

Authors:  Rebecca J Cox; Abdullah S Madhun; Solveig Hauge; Haakon Sjursen; Diane Major; Mirjam Kuhne; Katja Höschler; Melanie Saville; Frederick R Vogel; Wendy Barclay; Isabella Donatelli; Maria Zambon; John Wood; Lars R Haaheim
Journal:  Vaccine       Date:  2009-02-02       Impact factor: 3.641

7.  An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Authors:  Florian Krammer; Asne Jul-Larsen; Irina Margine; Ariana Hirsh; Haakon Sjursen; Maria Zambon; Rebecca J Cox
Journal:  Clin Vaccine Immunol       Date:  2014-06-18

Review 8.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

9.  Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Authors:  Larisa Rudenko; Irina Kiseleva; Anatoly N Naykhin; Marianna Erofeeva; Marina Stukova; Svetlana Donina; Galina Petukhova; Maria Pisareva; Vera Krivitskaya; Michael Grudinin; Zhanna Buzitskaya; Irina Isakova-Sivak; Svetlana Kuznetsova; Natalie Larionova; Julia Desheva; Irina Dubrovina; Alexandra Nikiforova; John C Victor; Kathy Neuzil; Jorge Flores; Vadim Tsvetnitsky; Oleg Kiselev
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

10.  Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).

Authors:  Mahdee Sobhanie; Yumiko Matsuoka; Sinthujan Jegaskanda; Theresa Fitzgerald; Raburn Mallory; Zhongying Chen; Catherine Luke; John Treanor; Kanta Subbarao
Journal:  J Infect Dis       Date:  2015-12-09       Impact factor: 5.226

View more
  132 in total

1.  Hemagglutinin Stalk-Reactive Antibodies Interfere with Influenza Virus Neuraminidase Activity by Steric Hindrance.

Authors:  Yao-Qing Chen; Linda Yu-Ling Lan; Min Huang; Carole Henry; Patrick C Wilson
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

2.  Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.

Authors:  Philipp A Ilinykh; Kai Huang; Rodrigo I Santos; Pavlo Gilchuk; Bronwyn M Gunn; Marcus M Karim; Jenny Liang; Mallorie E Fouch; Edgar Davidson; Diptiben V Parekh; James B Kimble; Colette A Pietzsch; Michelle Meyer; Natalia A Kuzmina; Larry Zeitlin; Erica Ollmann Saphire; Galit Alter; James E Crowe; Alexander Bukreyev
Journal:  Cell Host Microbe       Date:  2020-04-21       Impact factor: 21.023

3.  Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Authors:  Guha Asthagiri Arunkumar; Andriani Ioannou; Teddy John Wohlbold; Philip Meade; Sadaf Aslam; Fatima Amanat; Juan Ayllon; Adolfo García-Sastre; Florian Krammer
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

5.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

Review 6.  The role of genetics and antibodies in sepsis.

Authors:  Evangelos J Giamarellos-Bourboulis; Steven M Opal
Journal:  Ann Transl Med       Date:  2016-09

Review 7.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

8.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

Review 9.  A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza.

Authors:  Boopathy Ramakrishnan; Karthik Viswanathan; Kannan Tharakaraman; Vlado Dančík; Rahul Raman; Gregory J Babcock; Zachary Shriver; Ram Sasisekharan
Journal:  Trends Microbiol       Date:  2016-10-14       Impact factor: 17.079

10.  Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Authors:  Felix Broecker; Allen Zheng; Nungruthai Suntronwong; Weina Sun; Mark J Bailey; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.